Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer
CTR20221804Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vibostolimab + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Oct 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221804.